Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 3
Submit an article Journal homepage
639
Views
12
CrossRef citations to date
0
Altmetric
Original Article: Clinical

The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma

Huei-Ting TsaiBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
,
Ruth M. PfeifferBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
,
Joan WarrenDivision of Cancer Control and Population Sciences, National Cancer Institute, NIH, Bethesda, MD, USA
,
Wyndham WilsonMetabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
&
Ola LandgrenMetabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA;Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
Pages 682-687 | Received 18 Dec 2012, Accepted 24 Apr 2014, Published online: 15 Jul 2014

References

  • Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2005, based on November 2007 SEER data submission. Bethesda, MD: National Cancer Institute; 2008.
  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
  • Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927–1932.
  • Grann VR, Hershman D, Jacobson JS, et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 2006;107:1530–1541.
  • Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–905.
  • Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–717.
  • Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864–1871.
  • Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:3159–3165.
  • Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40: IV–3–18.
  • Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER- Medicare data to identify chemotherapy use. Med Care 2002;40: IV–55–61.
  • Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133–139.
  • Wilson W, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758–765.
  • Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18: 3633–3642.
  • Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573–1582.
  • Luminari S, Montanini A, Caballero D, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol 2010;21:1492–1499.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.